Denali Therapeutics Inc. (DNLI): EPS (Basic)
-$2.97
Year ended 2025-12-31
| Period ended | EPS (Basic) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$2.97 | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$2.57 | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$1.06 | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$2.60 | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$2.39 | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $0.65 | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$2.07 | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$0.39 | n/a | 2021-02-26, From 2018-01-01 |
EPS (Basic) at similar companies
| Company | Year ended | EPS (Basic) | Change YoY |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | -$2.97 | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $0.07 | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $14.33 | +88.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $0.87 | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$0.08 | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.17 | +148.9% |
| Biogen Inc. (BIIB) | 2025-12-31 | $8.83 | -21.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$0.28 | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $6.84 | n/m |
Compare DNLI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗